Designed by Freepik

RESEARCH

One of the major obstacles in clinical oncology is that tumors may often relapse, resist therapy and sometimes even spread despite an initial successful treatment. We have pioneered the idea that host effects generated in response to therapy are substantially involved in tumor resistance and could even lead to metastasis spread. We termed this phenomenon as “Host Response to Anti-Cancer Therapy”.

Our findings provide a larger view of the balance between anti-tumorigenic and pro-tumorigenic effects of cancer treatments, and therefore can pave the way for the development of novel treatment strategies against cancer.

Our study focuses on understanding why tumors relapse and spread despite initial treatment response

OUR TEAM

Yuval Shaked, PhD

Principal Investigator

Ziv Raviv, PhD

Lab Manager

Abhilash Deo, PhD

Post Doctoral Fellow

Madeleine Ben-Guigui, MSc

PhD Student

Rotem Menachem, MSc

PhD Student

Bar Manobla, MSc

PhD Student

Sapir Levin, MSc

PhD Student

Chen Buxbaum, MD

PhD Student

Chen Sharon, BSc

M.Sc Student

DISCOVERING NEW PATHWAYS

ADVANCING CANCER RESEARCH

IMPROVING CANCER THERAPY OUTCOMES

Photos by National Cancer Institute on Unsplash

PUBLICATIONS

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases.
Therapy-induced Recruitment of Circulating Endothelial Progenitor Cells to Tumors
T cells promote metastasis by regulating extracellular matrix remodeling following chemotherapy
Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects.
The protumorigenic host response to cancer therapy
G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist
Early Cardiac Remodeling Promotes Tumor Growth and Metastasis.
Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice

SUPPORT

Publications
Lab Members
Established

CONTACT

Yuval Shaked, PhD

Director

Rappaport-Technion Integrated Cancer Center 

Technion- Israel Institute of Technology 

Department of cell biology and cancer research

Rappaport Faculty of Medicine, 11th Floor 

1 Efron St. Bat Galim, Haifa, Israel, 31096

Office: 972-73-378-5215
Lab:  972-73-378-5238

  yshaked@technion.ac.il